MUC1 and neoplasm: found that the EGFR-TKI drug erlotinib, targeting MUC1-positive cervical cancer through the MUC1-EGFR-CREB/GRβ-IL-6 axis, significantly inhibits taxol-resistant tumor stem cells and reduces residual tumor stem cells after chemotherapy, offering the potential to improve patient prognosis (19).